uniQure NV Hits Day Low of $8.74 Amidst Intense Price Pressure

uniQure NV, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, with the stock hitting an intraday low of USD 8.74. The stock has seen a sharp decline of 14.0% on March 3, 2026, contrasting with a modest drop of 0.43% in the S&P 500 during the same period. Over the past week, uniQure NV's performance has been particularly stark, plummeting by 62.42%, while the S&P 500 has remained relatively stable with a decrease of just 0.44%. The one-month performance reflects a similar trend, with the stock down 67.52% compared to a 1.43% decline in the broader market. Financial metrics indicate challenges for uniQure NV, with net sales for the half-year at USD 8.96 million, representing a decline of 33.18%. The pre-tax profit for the quarter stands at a loss of USD 70.08 million, a significant drop of 72.04%. Additionally, the company's inventory turnover ratio is at its lowest, indicating potential inefficiencies. Overall, uniQure NV's recent performance underscores a period of notable difficulty, marked by substantial declines across various time frames.